TD Asset Management
QNCX icon

TD Asset Management’s Quince Therapeutics QNCX Stock Holding History

TD Asset Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26
Closed -$477K – 1532
2021
Q3 		$477K Buy
+26
New +$414K ﹤0.01% 1398
2020
Q3 		– Sell
-22
Closed -$204K – 1391
2020
Q2 		$204K Buy
+22
New +$202K ﹤0.01% 1292

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TD Asset Management's QNCX Position: Q4 2021 in Review

TD Asset Management sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 26 shares — an estimated $477K sold.

TD Asset Management first reported a position in QNCX in Q2 2020 and held it in 2 quarters. The position peaked at $477K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

  • TD Asset Management reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
  • TD Asset Management sold 26 Quince Therapeutics shares in Q4 2021, an estimated $477K.
  • TD Asset Management first reported a position in Quince Therapeutics in Q2 2020 and held it in 2 quarters.
  • TD Asset Management's Quince Therapeutics position peaked at $477K in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on TD Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.